Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives

Overview

Journal Biology (Basel)

Publisher MDPI

Specialty Biology

Date 2021 Sep 28

PMID 34571723

Citations 6

Authors

Alessandra Giustozzi

Vanda Salutari

Elena Giudice

Lucia Musacchio

Caterina Ricci

Chiara Landolfo

Maria Teresa Perri

Giovanni Scambia

Domenica Lorusso

Affiliations

Soon will be listed here.

Abstract

Endometrial carcinoma is the most frequent cancer of the reproductive female organs. Most endometrial cancers are diagnosed at early stage (75%). Treatment options depend on pathogenetic, histopathologic and clinical characteristic at the diagnosis. To improve patient management in the near future, recent research has focused on new molecular features; evidence has shown that these give a better definition of patient prognosis and can help in tailoring adjuvant treatments by identifying specific subgroups of patients whose tumors may benefit from specific therapeutic approaches. In this review, we will focus on current knowledge of adjuvant treatment of endometrial carcinoma, using a prognostic-risk group stratification based on pathogenetic, clinical and molecular features, and will take a look at the ongoing trials that will further change the therapeutic approach in coming years.

Citing Articles

Impact of Vaginal Dilator Use and 68 Gy EQD2 Dose Constraint on Vaginal Complications in External Beam Irradiation Followed by Brachytherapy in Post-Operative Endometrial Cancer.

Noorian F, Abellana R, Zhang Y, Herreros A, Lancellotta V, Tagliaferri L J Pers Med. 2024; 14(8).

PMID: 39202029 PMC: 11355937. DOI: 10.3390/jpm14080838.

It is time to implement molecular classification in endometrial cancer.

Bruno V, Logoteta A, Chiofalo B, Mancini E, Betti M, Fabrizi L Arch Gynecol Obstet. 2023; 309(3):745-753.

PMID: 37410149 DOI: 10.1007/s00404-023-07128-z.

Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study.

Martins D, OSullivan D, Boyne D, Cheung W, Allonby O, Habash M Curr Oncol. 2023; 30(2):2277-2289.

PMID: 36826137 PMC: 9955469. DOI: 10.3390/curroncol30020176.

The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.

Lopez-Janeiro A, Villalba-Esparza M, Brizzi M, Jimenez-Sanchez D, Ruz-Caracuel I, Kadioglu E J Pathol. 2022; 258(4):426-436.

PMID: 36169332 PMC: 9828119. DOI: 10.1002/path.6012.

Endometrial Cancer in Pre-Menopausal Women and Younger: Risk Factors and Outcome.

Abdol Manap N, Ng B, Phon S, Abdul Karim A, Lim P, Fadhil M Int J Environ Res Public Health. 2022; 19(15).

PMID: 35897440 PMC: 9330568. DOI: 10.3390/ijerph19159059.

References

Sant M, Chirlaque Lopez M, Agresti R, Sanchez Perez M, Holleczek B, Bielska-Lasota M . Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study. Eur J Cancer. 2015; 51(15):2191-2205. DOI: 10.1016/j.ejca.2015.07.022. View

Constantine G, Kessler G, Graham S, Goldstein S . Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors. J Womens Health (Larchmt). 2018; 28(2):237-243. PMC: 6390656. DOI: 10.1089/jwh.2018.6956. View

Shinde A, Li R, Amini A, Chen Y, Cristea M, Dellinger T . Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology. Gynecol Oncol. 2018; 151(1):82-90. DOI: 10.1016/j.ygyno.2018.08.028. View

de Boer S, Powell M, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C . Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19(3):295-309. PMC: 5840256. DOI: 10.1016/S1470-2045(18)30079-2. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Keys H, Roberts J, Brunetto V, Zaino R, Spirtos N, Bloss J . A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004; 92(3):744-51. DOI: 10.1016/j.ygyno.2003.11.048. View

Donovan E, Reade C, Eiriksson L, Pond G, Arora N, Elit L . Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer. Cureus. 2018; 10(9):e3387. PMC: 6267614. DOI: 10.7759/cureus.3387. View

Qu X, Velker V, Leung E, Kwon J, Elshaikh M, Kong I . The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis. Gynecol Oncol. 2018; 149(2):283-290. DOI: 10.1016/j.ygyno.2018.03.002. View

Ortoft G, Hansen E, Bertelsen K . Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study. Int J Gynecol Cancer. 2013; 23(8):1429-37. DOI: 10.1097/IGC.0b013e3182a5e77d. View

10.

Cho K, Cooper K, Croce S, Djordevic B, Herrington S, Howitt B . International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group. Int J Gynecol Pathol. 2018; 38 Suppl 1:S114-S122. PMC: 6296838. DOI: 10.1097/PGP.0000000000000496. View

11.

Hogberg T, Signorelli M, de Oliveira C, Fossati R, Lissoni A, Sorbe B . Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010; 46(13):2422-31. PMC: 3552301. DOI: 10.1016/j.ejca.2010.06.002. View

12.

Aalders J, Abeler V, KOLSTAD P, Onsrud M . Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980; 56(4):419-27. View

13.

Kandoth C, Schultz N, Cherniack A, Akbani R, Liu Y, Shen H . Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447):67-73. PMC: 3704730. DOI: 10.1038/nature12113. View

14.

Matei D, Filiaci V, Randall M, Mutch D, Steinhoff M, DiSilvestro P . Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019; 380(24):2317-2326. PMC: 6948006. DOI: 10.1056/NEJMoa1813181. View

15.

Talhouk A, McConechy M, Leung S, Li-Chang H, Kwon J, Melnyk N . A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015; 113(2):299-310. PMC: 4506381. DOI: 10.1038/bjc.2015.190. View

16.

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

17.

Nout R, Smit V, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010; 375(9717):816-23. DOI: 10.1016/S0140-6736(09)62163-2. View

18.

Wortman B, Creutzberg C, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9):1067-1074. PMC: 6219495. DOI: 10.1038/s41416-018-0310-8. View

19.

Vermij L, Smit V, Nout R, Bosse T . Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2019; 76(1):52-63. PMC: 6972558. DOI: 10.1111/his.14015. View

20.

Van den Heerik A, Horeweg N, Nout R, Lutgens L, van der Steen-Banasik E, Westerveld G . PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020; 30(12):2002-2007. PMC: 7788476. DOI: 10.1136/ijgc-2020-001929. View